Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 2002;99:183-187
© 2002 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connor, J. P.
Right arrow Articles by Goldberg, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connor, J. P.
Right arrow Articles by Goldberg, J. M.

ORIGINAL RESEARCH

Empiric Vaginal Metronidazole in the Management of the ASCUS Papanicolaou Smear: A Randomized Controlled Trial

Joseph P. Connor, MD, Gloria Elam, MD, MPH and Jeffrey M. Goldberg, MD

From the Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, Illinois.

Address reprint requests to: Joseph P. Connor, MD, The University of Wisconsin, Department of Obstetrics and Gynecology, H4/636 CSC, 600 Highland Avenue, Madison, WI 53792; E-mail: jpconnor{at}facstaff.wisc.edu.

OBJECTIVE: To determine whether empiric treatment with vaginal metronidazole in women with atypical squamous cells of undetermined significance (ASCUS) on Papanicolaou smear increases the number of cases that regress to normal on repeated cytologic studies.

METHODS: A randomized double-masked trial was designed to compare women with ASCUS on screening Papanicolaou smear who received vaginal metronidazole, 37.5 mg twice daily, or placebo gel twice daily, for 5 days. Normalization of repeated Papanicolaou smear at 3 months was the primary end point. Regression to normal between the two groups was compared by {chi}2 analysis. Power analysis required 45 women per study arm to demonstrate a 50% improvement in regression to normal among the metronidazole-treated women, at {alpha} = 0.05 and 80% power.

RESULTS: One hundred and six tubes of gel were dispensed, 54 metronidazole and 52 placebo. Eighty-four women (79%) returned for repeated cytologic examination at a mean of 6.5 months. Overall, 50 women (60%) had normal findings on repeated cytologic examination, and 34 (40%) had persistent abnormal findings. Twenty-two women had repeated ASCUS, and 11 had squamous intra-epithelial lesions (SIL) on repeated cytologic examination. Regression to normal was found in 22 (54%) metronidazole-treated women and 28 (65%) placebo recipients. The number of cases of repeated ASCUS (31% versus 25%) or SIL (15% versus 10%) were similar between the two groups.

CONCLUSIONS: Empiric vaginal metronidazole does not improve the management of women with ASCUS on Papanicolaou smear and should be discouraged.




This article has been cited by other articles:


Home page
JWatch Women's HealthHome page
Antibiotic Therapy for ASCUS Is Ineffective
Journal Watch Women's Health, April 9, 2002; 2002(409): 3 - 3.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Obstetricians and Gynecologists.